Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Soluble ST2 Levels and Left Ventricular Structure and Function in Patients With Metabolic Syndrome

  • Received : 2016.02.28
  • Accepted : 2016.07.27
  • Published : 2016.11.01
⟨ Previous Next ⟩

Abstract

Background: A biomarker that is of great interest in relation to adverse cardiovascular events is soluble ST2 (sST2), a member of the interleukin family. Considering that metabolic syndrome (MetS) is accompanied by a proinflammatory state, we aimed to assess the relationship between sST2 and left ventricular (LV) structure and function in patients with MetS. Methods: A multicentric, cross-sectional study was conducted on180 MetS subjects with normal LV ejection fraction as determined by echocardiography. LV hypertrophy (LVH) was defined as an LV mass index greater than the gender-specific upper limit of normal as determined by echocardiography. LV diastolic dysfunction (DD) was assessed by pulse-wave and tissue Doppler imaging. sST2 was measured by using a quantitative monoclonal ELISA assay. Results: LV mass index (${\beta}=0.337$, P<0.001, linear regression) was independently associated with sST2 concentrations. Increased sST2 was associated with an increased likelihood of LVH [Exp (B)=2.20, P=0.048, logistic regression] and increased systolic blood pressure [Exp (B)=1.02, P=0.05, logistic regression]. Comparing mean sST2 concentrations (adjusted for age, body mass index, gender) between different LV remodeling patterns, we found the greatest sST2 level in the group with concentric hypertrophy. There were no differences in sST2 concentration between groups with and without LV DD. Conclusions: Increased sST2 concentration in patients with MetS was associated with a greater likelihood of exhibiting LVH. Our results suggest that inflammation could be one of the principal triggering mechanisms for LV remodeling in MetS.

Keywords

References

  1. Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation 2006.
  2. Hunt KJ, ResendezRG, Williams K, Haffner SM, Stern MP; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251-7. https://doi.org/10.1161/01.CIR.0000140762.04598.F9
  3. Kim SH. Metabolic syndrome and myocardial contractile reserve. J Cardiovasc Ultrasound 2011;19:174-5. https://doi.org/10.4250/jcu.2011.19.4.174
  4. de las Fuentes L, Brown AL, Mathews SJ, Waggoner AD, Soto PF, Gropler RJ, et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J 2007;28:553-9.
  5. Tadic M, Ivanovic B, Kostic N, Simic D, Matic D, Celic V. Metabolic syndrome and left ventricular function: is the number of criteria actually important? Med Sci Monit 2012;18:282-9.
  6. O'Neil L. The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. BiochemSoc Trans 2000;28:557-63. https://doi.org/10.1042/bst0280557
  7. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186-90. https://doi.org/10.1161/01.CIR.0000127958.21003.5A
  8. Rehman SU, Mueller T, JanuzziJL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am CollCardiol 2008;52:1458-65. https://doi.org/10.1016/j.jacc.2008.07.042
  9. Weinberg EO, Shimpo M, De KeulenaerGW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961-6. https://doi.org/10.1161/01.CIR.0000038705.69871.D9
  10. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-6. https://doi.org/10.1161/01.CIR.0000047274.66749.FE
  11. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012; 58:1673-81. https://doi.org/10.1373/clinchem.2012.192153
  12. Ojji DB, Opie LH, Lecour S, Lacerda L, Adeyemi O, Sliwa K. Relationship between left ventricular geometry and soluble ST2 in a cohort of hypertensive patients. J Clin Hypertens 2013;15:899-904. https://doi.org/10.1111/jch.12205
  13. Zeyda M, Wernly B, Demyanets S, Kaun C, Hämmerle M, Hantusch B, et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes 2013;37:658-65. https://doi.org/10.1038/ijo.2012.118
  14. Fousteris E, Melidonis A, Panoutsopoulos G, Tzirogiannis K, Foussas S, Theodosis-Georgilas A, et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol 2011;10:101. https://doi.org/10.1186/1475-2840-10-101
  15. Chen LQ, de Lemos JA, Das SR, Ayers CR, Rohatgi A. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin Chem 2013;59:536-46. https://doi.org/10.1373/clinchem.2012.191106
  16. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219. https://doi.org/10.1093/eurheartj/eht151
  17. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome:ajoint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
  18. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80. https://doi.org/10.1111/j.1464-5491.2006.01858.x
  19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39. https://doi.org/10.1016/j.echo.2014.10.003
  20. Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA; Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002;15:167-84. https://doi.org/10.1067/mje.2002.120202
  21. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10:165-93.
  22. Oh JK, Park SJ, Nagueh SF. Established and novel clinical applications of diastolic function assessment by echocardiography. Circ Cardiovasc Imaging 2011;4:444-55. https://doi.org/10.1161/CIRCIMAGING.110.961623
  23. Westcott DJ, DelpropostoJB, Geletka LM, Wang T, Singer K, Saltiel AR, et al. MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. J Exp Med 2009;206: 3143-56. https://doi.org/10.1084/jem.20091333
  24. Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, et al. A novel cardiac bio-marker: ST2: areview. Molecules 2013;18: 15314-28. https://doi.org/10.3390/molecules181215314
  25. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013;39:1003-18. https://doi.org/10.1016/j.immuni.2013.11.010
  26. Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol 2013;60:16-26. https://doi.org/10.1016/j.yjmcc.2013.03.020
  27. Wang YC, Yu CC, Chiu FC, Tsai CT, Lai LP, Hwang JJ, et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail 2013;19:163-8. https://doi.org/10.1016/j.cardfail.2013.01.010

Cited by

  1. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases vol.8, pp.None, 2017, https://doi.org/10.3389/fimmu.2017.00475
  2. IL-33 (Interleukin 33)/sST2 Axis in Hypertension and Heart Failure vol.72, pp.4, 2016, https://doi.org/10.1161/hypertensionaha.118.11157
  3. IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis vol.9, pp.None, 2018, https://doi.org/10.3389/fpsyt.2018.00271
  4. Regulation of Energy Expenditure and Brown/Beige Thermogenic Activity by Interleukins: New Roles for Old Actors vol.19, pp.9, 2016, https://doi.org/10.3390/ijms19092569
  5. Relationship between Soluble ST2 and Left Ventricular Geometry in Maintenance Hemodialysis Patients vol.50, pp.1, 2016, https://doi.org/10.1159/000508402